For patients with hematologic malignancies such as leukemias, lymphomas and other related cancers, allogeneic hematopoietic cell transplantation (allo HCT) is a critically important therapy that can produce cures when other treatments cannot. Roughly 20,000 patients undergo allo BMT world-wide each year. A major risk of allo HCT continues to be graft-versus-host disease (GVHD), which results from the donor immune system recognizing the transplant recipient?s organs as foreign, leading to life-threatening inflammation. Developing strategies that reduce GVHD but leave global immune function intact should produce a major benefit for patients. One promising approach that we propose testing is targeting the subset of intestinal commensal bacteria that are capable of consuming and degrading mucins, which play a critical role in maintaining the intestinal epithelial barrier and immunological homeostasis. In this proposal, we present preliminary data identifying two common scenarios during the allo HCT process: 1) poor oral dietary intake due to conditioning or development of GVHD, and 2) administration of broad-spectrum antibiotics. Both of these often lead to increases in mucolytic bacteria. Further, we have identified antibiotic and metabolic strategies to suppress mucolytic bacteria activity. We will apply these insights to guide a mucus-focused evaluation of GVHD, in both mouse models and in stool biospecimens collected from allo HCT patients. We and others have identified the microbiota as a potent modulator of acute GVHD severity. This project proposes capitalizing on a mechanistic insight into how this can occur, with clear translational potential.

Public Health Relevance

For many patients with blood cancers, undergoing allogeneic bone marrow transplantation is the only chance for cure, but comes with a serious risk for developing inflammation of the intestines that can be life- threatening. In this application, we propose exploring strategies in these patients to protect the mucus layer in the large intestine, which plays a key role in separating the lining of the intestine from the bacteria that reside within the intestine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL124112-06
Application #
10058054
Study Section
Transplantation, Tolerance, and Tumor Immunology Study Section (TTT)
Program Officer
Welniak, Lisbeth A
Project Start
2015-08-15
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Plantinga, Anna; Zhan, Xiang; Zhao, Ni et al. (2017) MiRKAT-S: a community-level test of association between the microbiota and survival times. Microbiome 5:17
Chaudhry, Mohammed S; Velardi, Enrico; Malard, Florent et al. (2017) Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. J Immunol 198:40-46
Peled, Jonathan U; Devlin, Sean M; Staffas, Anna et al. (2017) Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol 35:1650-1659
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Galloway-Peña, Jessica R; Jenq, Robert R; Shelburne, Samuel A (2017) Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient? Clin Cancer Res 23:3263-3268
Peled, Jonathan U; Jenq, Robert R (2017) Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant. Leuk Lymphoma 58:759-761
Shono, Yusuke; Docampo, Melissa D; Peled, Jonathan U et al. (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8:339ra71
Chaudhry, Mohammed S; Velardi, Enrico; Dudakov, Jarrod A et al. (2016) Thymus: the next (re)generation. Immunol Rev 271:56-71